Ivonescimab
Multispecific antibody
Evidence outlook
Approved: ivonescimab in combination with chemotherapy for the first-line treatment of advanced... (CN)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Reliable signal
Also in development:Metastatic Colorectal Cancer · Phase 3 · investigational in the USBiliary Tract Cancer · Phase 3 · investigational in the US · under NMPA review
Also approved (3)
- ivonescimab in combination with chemotherapy for the first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC)
- monotherapy for the first-line treatment of PD-L1-positive (TPS ≥ 1%) non-small cell lung cancer (NSCLC)
- ivonescimab combined with platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with an EGFR tyrosine kinase inhibitor (TKI)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05499390 NCT05499390 · Advanced Non-small-cell Lung Cancer This trial randomized patients in a quadruple-blinded design comparing ivonescimab against an active comparator (pembrolizumab), with nearly 400 participants -- a reasonably powered sample for a Phase 3 oncology trial. The primary endpoint, progression-free survival by independent blinded review, is a hard clinical measure, and the result was statistically significant in favor of ivonescimab (11.1 vs 5.8 months, hazard ratio 0.51, p<0.0001), indicating a clear and well-supported benefit. Registry: NCT05499390 | 3 | PFS assessed by IRRC per RECIST v1.1 (Up to 2 approximately years) 2024-01-29 | HARMONi-2 (NCT05499390), independent-review PFS at the interim analysis: ivonescimab 11.1 vs pembrolizumab 5.8 months; HR 0.51 (95% CI 0.38-0.69), one-sided p<0.0001; 398 randomized | Reliable signal | link ↗ |
View 4 more trials
NCT05184712 NCT05184712 · Non-Squamous Non-small Cell Lung Cancer This was a randomized, quadruple-blinded, placebo-controlled Phase 3 trial with over 300 patients, using progression-free survival (a hard clinical endpoint) as its primary measure. A published result shows ivonescimab plus chemotherapy significantly extended PFS compared to placebo plus chemotherapy (7.1 vs 4.8 months, HR 0.46, P<.001), meeting the primary endpoint in the favorable direction. Registry: NCT05184712 | 3 | Progression-free survival (PFS) (Up to 2 years) 2023-03-10 | HARMONi-A (NCT05184712), independent-review PFS: ivonescimab plus chemotherapy 7.1 vs placebo plus chemotherapy 4.8 months; HR 0.46 (95% CI 0.34-0.62), P<.001 | Reliable signal | link ↗ |
NCT05899608 NCT05899608 · Non-Small Cell Lung Cancer Registry: NCT05899608 | 3 | Overall Survival (OS) (approximately 4 years); Progression Free Survival (PFS) (approximately 3 years) 2028-12-31 | In progress: results expected 31 Dec 2028 | not yet graded | link ↗ |
NCT06928389 NCT06928389 · Non-Small Cell Lung Cancer Registry: NCT06928389 | 3 | Overall Survival (OS) (approximately 5 years) 2027-05 | In progress: results expected 1 May 2027 | not yet graded | link ↗ |
NCT04900363 NCT04900363 · Non-small Cell Lung Cancer The study assigned all participants to ivonescimab without randomization, blinding, or a comparison arm. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Registry: NCT04900363 | 1/2 | Objective response rates (ORR) (Up to approximately 2 years); Number of participants with adverse events (AEs) (Up to approximately 2 years); Progression-free survival (PFS) (Up to approximately 2 years) 2024-06-28 | ORR 39.8% and DCR 86.1% in 108 patients; first-line PD-L1-positive ORR 33.3%, 52.6%, 60.0%, 75.0% by dose (10 mg/kg Q3W, 20 mg/kg Q2W, 20 mg/kg Q3W, 30 mg/kg Q3W); grade >=3 TRAEs 22.2% | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (15)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (118)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (33)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (15)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 1/2 (1)
What this study did
Competitive landscape
Other PD-1 + VEGFA drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Biliary Tract Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ivonescimab: this drug | Phase 3 | Multispecific antibody | PD-1 + VEGFA | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | NCT04003636: Overall Survival (OS) (Up to approximately 38 months): Arm A: Pembrolizumab + Chemotherapy 12.7 Months (95% CI 11.5 to 13.6) | Arm B: Placebo + Chemotherapy 10.9 Months (95% CI 9.9 to 11.6) | |
| Zanidatamab | Approved | Multispecific antibody | HER2 | Weak signal | NCT04466891: Confirmed ORR 41.3% (95% CI 30.4-52.8); median duration of response 12.9 months (Lancet Oncol 2023) | |
| Futibatinib (Lytgobi) | Phase 3 | Small molecule | FGFR (FGFR1/2/3/4) | not yet graded | No reviewed efficacy summary in this indication | |
| Izalontamab Brengitecan | Phase 3 | Antibody–drug conjugate | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| Rilvegostomig | Phase 3 | Multispecific antibody | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Brengitecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Tovecimig | Phase 2/3 | Multispecific antibody | DLL4 x VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ramucirumab | Phase 2 | Monoclonal antibody | VEGFR2 | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(133 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Ivonescimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (12)
December 2026 (12)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (61)
January 2027 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
February 2027 (1)
What to watch
March 2027 (1)
What to watch
April 2027 (2)
May 2027 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
June 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
July 2027 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
August 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
September 2027 (4)
What to watch
What to watch
What to watch
What to watch
October 2027 (3)
What to watch
What to watch
What to watch
November 2027 (2)
What to watch
What to watch
December 2027 (18)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (41)
January 2028 (4)
What to watch
What to watch
What to watch
What to watch
February 2028 (2)
March 2028 (4)
What to watch
What to watch
What to watch
What to watch
April 2028 (4)
What to watch
What to watch
What to watch
What to watch
May 2028 (3)
What to watch
What to watch
What to watch
June 2028 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
July 2028 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
August 2028 (2)
September 2028 (2)
October 2028 (2)
November 2028 (2)
December 2028 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2029 (11)
January 2029 (1)
What to watch
February 2029 (2)
March 2029 (1)
What to watch
April 2029 (2)
May 2029 (2)
June 2029 (2)
What to watch
What to watch
August 2029 (1)
What to watch
2030 (4)
May 2030 (1)
What to watch
June 2030 (1)
What to watch
October 2030 (1)
What to watch
December 2030 (1)
What to watch
2031 (2)
May 2031 (1)
What to watch
November 2031 (1)
What to watch
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent